UPDATE: Canaccord Genuity Initiates Coverage on ImmunoGen Ahead of Phase 3 Data

In a report published Wednesday, Canaccord Genuity analyst John Newman initiated coverage on ImmunoGen IMGN with a Buy rating and $20.00 price target. In the report, Canaccord Genuity noted, “We are initiating coverage of ImmunoGen with a BUY rating and $20 price target. We expect positive Phase 3 data for Kadcyla in HER2+ metastatic breast cancer, which could eliminate the need for chemotherapy in this setting. Kadcyla targets a >$7B market opportunity long term, with royalties to ImmunoGen. ImmunoGen is also advancing its wholly-owned products.” ImmunoGen closed on Tuesday at $12.80.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorInitiationAnalyst RatingsCanaccord GenuityJohn Newman
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!